Article Link: Once-Daily Trelegy Ellipta Gains Expanded Indication in the US for the Treatment of Patients with COPD 24 April 2018 —...
FDA Approves Intravenous Formulation of Akynzeo (fosnetupitant/palonosetron) for Chemotherapy-Induced Nausea and Vomiting
Article Link: FDA Approves Intravenous Formulation of Akynzeo (fosnetupitant/palonosetron) for Chemotherapy-Induced Nausea and Vomiting L...
FDA Approves Tagrisso (osimertinib) as First-Line Treatment for EGFR-Mutated Non-Small Cell Lung Cancer
Article Link: FDA Approves Tagrisso (osimertinib) as First-Line Treatment for EGFR-Mutated Non-Small Cell Lung Cancer 18 April 2018 ̵...
FDA Approves Crysvita (burosumab-twza) for X-Linked Hypophosphatemia
Article Link: FDA Approves Crysvita (burosumab-twza) for X-Linked Hypophosphatemia April 17, 2018 — The U.S. Food and Drug Administ...
FDA Approves Tavalisse (fostamatinib disodium hexahydrate) for Chronic Immune Thrombocytopenia
Article Link: FDA Approves Tavalisse (fostamatinib disodium hexahydrate) for Chronic Immune Thrombocytopenia SOUTH SAN FRANCISCO, Calif.,...
FDA Approves Afinitor Disperz (everolimus) for Tuberous Sclerosis Complex-Associated Partial-Onset Seizures
Article Link: FDA Approves Afinitor Disperz (everolimus) for Tuberous Sclerosis Complex-Associated Partial-Onset Seizures April 11, 2018 ...
Pacira Announces FDA Approval of Exparel as a Nerve Block to Produce Regional Analgesia
Article Link: Pacira Announces FDA Approval of Exparel as a Nerve Block to Produce Regional Analgesia PARSIPPANY, N.J., April 06, 2018 (G...
Rubraca (rucaparib) Approved in the U.S. as Maintenance Treatment of Recurrent Ovarian Cancer
Article Link: Rubraca (rucaparib) Approved in the U.S. as Maintenance Treatment of Recurrent Ovarian Cancer BOULDER, Colo.–(BUSINES...
FDA Approves Bydureon (exenatide extended-release) for Use with Basal Insulin in Patients with Type 2 Diabetes with Inadequate Glycemic Control
Article Link: FDA Approves Bydureon (exenatide extended-release) for Use with Basal Insulin in Patients with Type 2 Diabetes with Inadequate Glycemic ...
FDA Expands Approval of Blincyto (blinatumomab) to Treat Minimal Residual Disease-Positive B-Cell Precursor Acute Lymphoblastic Leukemia
Article Link: FDA Expands Approval of Blincyto (blinatumomab) to Treat Minimal Residual Disease-Positive B-Cell Precursor Acute Lymphoblastic Leukemia...
